CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20-954

MEDICAL REVIEW(S)
NDA Medical Review

NDA 20-954

Busulfex™
(busulfan)

Applicant:
Orphan Medical

Date of Submission:
August 3, 1998
1. INTRODUCTION ................................................................. 6
   1.1 Basic Information and Timeline .................................. 6
   1.2 Drug Name and Chemical Characteristics ................. 6
      1.2.1 Generic Name ............................................. 6
      1.2.2 Trade name ............................................. 6
      1.2.3 Chemical Name ......................................... 7
      1.2.4 Molecular Formula .................................... 7
      1.2.5 Molecular Weight ..................................... 7
      1.2.6 Chemistry/Manufacturing Controls .................. 7
   1.3 Pharmacologic Category ......................................... 7
      1.3.1 Indications and Off-Label Use .......................... 7
      1.3.2 Preclinical Pharmacology/Toxicology ................ 7
      1.3.3 Clinical Pharmacology/Pharmacokinetics ............ 7
   1.4 Paper and Electronic Submission ............................. 7
   1.5 Brief Overview of the Application and Its Issues ....... 8

2. Summary of Clinical Studies ......................................... 8
   2.1 Pivotal Trials .................................................... 8

3. Pivotal Study – OMC-BUS-3: A Phase 2 Study of High-Dose Intravenous Busulfan and Cyclophosphamide with Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Hematologic Malignancies .............. 9
   3.1 Rationale ............................................................ 9
   3.2 Objectives of the Study ......................................... 10
   3.3 Study Design ...................................................... 10
   3.4 Treatment Plan ................................................... 11
      3.4.1 Dose Modifications ..................................... 11
      3.4.2 Concomitant Medications ............................... 11
      3.4.3 Marrow Processing and Infusion ..................... 12
      3.4.4 Evaluation on Study .................................... 12
      3.4.5 Pharmacokinetic Studies ............................... 14
   3.5 Inclusion Criteria ................................................. 15
   3.6 Protocol Amendments ............................................. 16
      3.6.1 Amendment #1: February 28, 1997 .................... 16
      3.6.2 Amendment #3: October 1, 1997 ....................... 17
      3.6.3 Amendment #4: October 14, 1997 ..................... 17
   3.7 Enrollment, Protocol Violations, Removal From Study .... 17
      3.7.1 Protocol Violations Based on Eligibility Criteria .... 17
      3.7.2 Protocol Violations Based on Study Medication/Transplant Deviations .... 18
      3.7.3 Protocol Violations Based on Scheduled Assessments/Evaluations ........ 18
   3.8 Patient demographics and baseline characteristics; tumor characteristics .......... 19
   3.9 On-Study Therapy ................................................. 20
   3.10 Endpoints/Statistical Considerations ....................... 20
      3.10.1 Definitions of Efficacy Endpoints .................. 20
   3.11 Efficacy Analysis ................................................. 21
      3.11.1 Myeloablation .......................................... 21
      3.11.2 Engraftment ............................................ 21
      3.11.3 Late Graft Failure .................................... 26
      3.11.4 Relapse .................................................. 27
3.11.5 Survival ................................................................................................................. 28
3.12 Safety Analysis .......................................................................................................... 28
3.12.1 Adverse Events ..................................................................................................... 28
3.12.2 Deaths .................................................................................................................. 28
3.13 Pharmacokinetics – OMC-BUS-3 ............................................................................. 35
3.14 Summary and Conclusions – OMC-BUS-3 ................................................................. 36

4. Pivotal Study – OMC-BUS-4: A Phase 2 Study of High-Dose Busulfan and
Cyclophosphamide with Allogeneic Marrow or Peripheral Blood Progenitor Cell
Transplantation for Hematologic Malignancies ............................................................... 38
4.1 Rationale .................................................................................................................... 38
4.2 Objectives of the Study ............................................................................................. 39
4.3 Study Design ............................................................................................................. 39
4.3.1 Treatment Plan ...................................................................................................... 39
4.3.2 Dose Modifications .............................................................................................. 40
4.3.3 Concomitant Medications .................................................................................... 40
4.3.4 Marrow Processing and Infusion .......................................................................... 41
4.3.5 Evaluation on Study .............................................................................................. 41
4.3.6 Pharmacokinetic Studies ....................................................................................... 44
4.4 Inclusion Criteria ........................................................................................................ 44
4.5 Protocol Amendments ............................................................................................... 45
4.5.1 Amendment #1: February 28, 1997 ................................................................. 45
4.5.2 Amendment #2: July 30, 1997 ............................................................................ 45
4.5.3 Amendment #3: September 25, 1997 ................................................................. 45
4.5.4 Amendment #4: October 14, 1997 ................................................................. 45
4.6 Enrollment, Protocol Violations, Removal From Study ........................................... 45
4.6.1 Protocol Violations Based on Eligibility Criteria ............................................. 46
4.6.2 Protocol Violations Based on Study Medication/Transplant Deviations ........... 46
4.6.3 Protocol Violations Based on Scheduled Assessments/Evaluations ................. 47
4.7 Patient demographics and baseline characteristics; tumor characteristics .......... 47
4.8 On-Study Therapy .................................................................................................... 48
4.9 Endpoints/Statistical Considerations .................................................................... 49
4.9.1 Definitions of Efficacy Endpoints ....................................................................... 49
4.10 Efficacy Analysis .................................................................................................... 50
4.10.1 Myeloablation ...................................................................................................... 50
4.10.2 Engraftment ........................................................................................................ 50
4.10.3 Late Graft Failure ............................................................................................... 58
4.10.4 Relapse ................................................................................................................ 59
4.10.5 Survival ............................................................................................................... 59
4.11 Safety Analysis ........................................................................................................ 60
4.11.1 Adverse Events .................................................................................................. 60
4.11.2 Deaths ............................................................................................................... 71
4.12 Pharmacokinetics – OMC-BUS-4 ......................................................................... 73
4.13 Summary and Conclusions – OMC-BUS-4 ............................................................. 73

5. Pharmacokinetic Studies OMC-BUS-2 and Amendment #4 to OMC-BUS-3 and OMC-
BUS-4 ................................................................................................................................. 76
5.1 Amendment #4 Efficacy Summary ......................................................................... 77
5.2 Amendment #4 Safety Summary .............................................................................. 77

6. Dimethylacetamide Toxicity ......................................................................................... 77
Table 7  Summary of Adverse Events, Grade 3 and 4 Toxicities, and SAE’s
Table 8  Summaries of Bilirubin and SGPT in Patients with Liver Abnormalities Reported as Adverse Events
Table 9  Summary of Safety Data from Phase 3 Autologous Studies Utilizing Busulfan Included in the Literature Review Section of the NDA Review
Table 10  Baseline Characteristics of Participants on OMC-BUS-4; Derived From Sponsor Table 1.1 Summary of Patient Disease/Disease Status at Enrollment, Volume 1.42
Table 11  Summary Patient Hematology Data in Patients with a Significant Drop in ANC After Engraftment
Table 12  Engraftment Date Assignment Differences Between Sponsor and Reviewer
Table 13  Summary of Patient Characteristics and Busulfan AUC’s for Patients with VOD; Derived from Sponsor Table 12.1 – Summary Data for Patients with VOD, Vol. 1.42
Table 14  Summaries of Bilirubin and SGPT in Patients with Liver Abnormalities Reported as Adverse Events
Table 15  Summary of Pulmonary Function Test Changes on Study; Derived from Sponsor Table 14.3.7 Summary of Pre-treatment and Post-Transplant Pulmonary Function Tests, Vol. 1.42
Table 16  Safety Summary of Allogeneic Transplantation Randomized Trials Presented in the NDA’s Literature Review
Table 17  Summary of Dimethylacetamide Phase I Dose Related Toxicity as Published by Weiss, et. al. Relative to a BUSULFEX™ Conditioning Regimen Dose
Table 18  Tabulation of Patients Experiencing DMA Neurological Toxicity in a Phase I Setting Relative to a BUSULFEX™ Conditioning Regimen Dose
Table 19  Summary List of Sponsor’s Core Database Articles Pertaining to AML
Table 20  Summary List of Additional Pertinent AML Studies Identified by Reviewer
Table 21  Summary of Level I Studies Pertaining to AML
Table 22  Summary of Non-Level I Supportive Studies in AML
Table 23  Summary List of Sponsor’s Core Dataset Articles Pertaining to CML
Table 24  Summary List of Additional Pertinent CML Studies Identified by Reviewer
Table 25  Summary of Level I Studies Pertaining to CML
Table 26  Summary List of Sponsor’s Core Database Articles Pertaining to ALL
Table 27  Summary List of Additional Pertinent ALL Studies Identified by Reviewer
Table 28  Summary of Level I Studies Pertaining to ALL
Table 29  Summary List of Sponsor’s Core Dataset Articles Pertaining to Non-Hodgkin’s Lymphoma
Table 30  Summary List of Additional Pertinent Non-Hodkin’s Lymphoma Studies Identified by the Reviewer
Table 31  Summary List of Sponsor’s Core Database Articles Pertaining to Hodgkin’s Disease
Table 32  Summary List of Additional Pertinent Hodgkin’s Disease Studies Identified by the Reviewer
Table 33  Summary List of Sponsor’s Core Database Articles Pertaining to Myelodysplastic Syndrome
Table 34  Summary List of Additional Pertinent Myelodysplastic Syndrome Studies Identified by the Reviewer
Table 35  Summary of Studies Pertaining to Myelodysplastic Syndrome
Table 36  Summary List of Sponsor’s Core Database Articles Pertaining to Multiple Myeloma
Table 37  Summary List of Additional Pertinent Multiple Myeloma Studies Identified by the Reviewer
Table 38  Summary List of Sponsor’s Core Database Articles Pertaining to Breast Carcinoma
Table 39  Summary List of Additional Pertinent Breast Carcinoma Studies Identified by the Reviewer ................................................................. 144
Table 40  Summary List of Sponsor’s Core Dataset Articles Pertaining to Solid Tumors .... 147
Table 41  Summary List of Sponsor’s Core Dataset Articles Pertaining to Genetic Diseases ... 148
Table 42  Summary of Level I Evidence by Disease .................................................. 150
Table 43  Summary of Engraftment Data from the Randomized Studies in Allogeneic Transplantation for CML ...................................................... 154
1. INTRODUCTION

1.1 Basic Information and Timeline

Table I Basic Application Information

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Busulfex™ (busulfan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Orphan Medical</td>
</tr>
<tr>
<td>NDA #20-954</td>
<td></td>
</tr>
<tr>
<td>Proposed Indication</td>
<td>For use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation. Diseases in which patient benefit from this mode of therapy have been demonstrated include acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, multiple myeloma, myelodysplastic syndrome, breast cancer, ovarian cancer, and genetic diseases. The patient’s disease status should either be refractory to other therapies or carry sufficiently high-risk for recurrence of disease that progenitor cell transplant is the treatment of choice in the opinion of a qualified physician.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-NDA meeting</td>
<td>January 16, 1997</td>
</tr>
<tr>
<td>NDA Submission date</td>
<td>August 3, 1998</td>
</tr>
<tr>
<td>NDA Drug Classification</td>
<td>Priority</td>
</tr>
<tr>
<td>Pharmacological category</td>
<td>Bifunctional alkylating agent</td>
</tr>
<tr>
<td>45-day meeting</td>
<td></td>
</tr>
<tr>
<td>60-day meeting</td>
<td></td>
</tr>
<tr>
<td>ODAC meeting</td>
<td>January 1998</td>
</tr>
</tbody>
</table>

1.2 Drug Name and Chemical Characteristics

1.2.1 Generic Name:

Busulfan

1.2.2 Trade name

Busulfex
1.2.3 Chemical Name:
1,4-butanediol-dimethanesulfonate esters
1,4-bis (methanesulfonyloxy)butane
1,4-di(methanesulfonyloxy)butane
1,4-di (methylsulfonyloxy)butane
1,4-butanediolbis (methanesulfonate)
methanesulfonic acid tetramethylene ester
tetramethylene bis(methanesulfonate)

1.2.4 Molecular Formula
C₉H₁₄O₈S₂

1.2.5 Molecular Weight:
246.31 g

1.2.6 Chemistry/Manufacturing Controls:
See chemistry review for details.

1.3 Pharmacologic Category:
Antineoplastic Agent. Bifunctional alkylating agent.

1.3.1 Indications and Off-Label Use
None.

1.3.2 Preclinical Pharmacology/Toxicology
See pharmacology/toxicology review for details.

1.3.3 Clinical Pharmacology/Pharmacokinetics
See clinical pharmacology/PK report for details

1.4 Paper and Electronic Submission
The application consisted of a complete archival copy of 116 volumes. The clinical and statistical data section, Section 8, consisted of Volumes 31-116. The sponsor’s review of the literature evidence for the efficacy and safety of oral busulfan as conditioning therapy for bone marrow transplantation was submitted in Volumes 51-53. Electronic data sets were submitted in
SAS and ACCESS. Annotated CRF’s were submitted in section 10.6, Volume 65, of the application.

1.5 Brief Overview of the Application and Its Issues

Busulfex™ is an intravenous formulation of busulfan. From a clinical standpoint, the safety and efficacy of this new method of administration of an old drug were addressed in this application through the submission of pharmacokinetic data, the results of two phase 2 studies employing the intravenous formulation, and an extensive literature review of oral busulfan’s use in conditioning therapy for transplantation. The phase 2 studies were performed to provide evidence that the safety and efficacy of the intravenous formulation were comparable to that of oral busulfan in the setting of conditioning for hematopoietic stem cell transplantation (autologous and allogeneic). The efficacy endpoints examined in these two phase 2 trials were myeloablation and engraftment. The purpose of the literature review component of this application was to establish the diseases for which hematopoietic stem cell transplantation with a busulfan-containing conditioning regimen has been established as effective and safe. Thus, the clinical issues addressed in this application include:

- Is the pharmacokinetic profile of the intravenous formulation of busulfan similar to that of the oral formulation?

- Do the phase 2 studies establish comparable efficacy (in the setting of hematopoietic stem cell transplantation) of the intravenous formulation and oral busulfan in terms of the endpoints – myeloablation and engraftment?

- Do the phase 2 studies establish that the safety of the intravenous formulation is comparable to that of oral busulfan when given in high doses as part of a conditioning regimen for hematopoietic stem cell transplantation?

- Does the literature establish that high dose oral busulfan is safe and efficacious when given as part of a conditioning regimen for hematopoietic stem cell transplantation? If so, in which diseases and specific settings?

These issues will be addressed in this review by first reviewing the results of the pivotal phase 2 studies submitted in this application. A discussion of the literature review will follow in Section 6.0. The reader is referred to the Biopharmaceutics Review for a detailed discussion of the pharmacokinetic issues involved in this application.

2. Summary of Clinical Studies

2.1 Pivotal Trials

The sponsor has submitted the study reports from 3 clinical trials that employed Busulfex (busulfan) Injection in combination with cyclophosphamide as conditioning therapy for hematopoietic progenitor cell transplantation. The first study, OMC-BUS-2, was a phase 1 dose escalation study in which patients with a variety of hematological malignancies received a single dose of Busulfex, followed by 15 doses of oral busulfan, as part of conditioning therapy for either
autologous or allogeneic bone marrow and/or peripheral stem cell infusion. The remaining two studies, OMC-BUS-3 and OMC-BUS-4, were both phase 2 studies in which the entire course of busulfan in the conditioning regimen was administered as Busulfex (busulfan) Injection. In OMC-BUS-3 patients with hematological malignancies underwent autologous bone marrow and/or peripheral stem cell transplantation. In OMC-BUS-4 participants with hematological malignancies underwent allogeneic bone marrow and/or peripheral stem cell transplantation. A table summarizing these studies follows.

Table 2  Study Summary Table

<table>
<thead>
<tr>
<th>Study No.</th>
<th>Design</th>
<th>No. Pts.</th>
<th>Population</th>
<th>Type of Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMC-BUS-2</td>
<td>Phase 1, dose escalation trial. Multi-center, open-label. Single dose</td>
<td>15</td>
<td></td>
<td>Autologous or Allogeneic</td>
</tr>
<tr>
<td>OMC-BUS-3</td>
<td>Phase 2, Multi-center, Open label</td>
<td>42</td>
<td>Lymphoma=35</td>
<td>Malignant Marrow or PBSC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Leukemia=7</td>
<td></td>
</tr>
<tr>
<td>OMC-BUS-4</td>
<td>Phase 2, Multi-center, Open label</td>
<td>62</td>
<td>Lymphoma=9</td>
<td>Malignant Marrow or PBSC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Leukemia=26</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CML = 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MDS = 9</td>
<td></td>
</tr>
</tbody>
</table>

In addition, the pharmacokinetic and safety data from patients treated on an Amendment to OMC-BUS-3 (N=3) and OMC-BUS-4 (N=9) have been submitted. Patients treated under this amendment received a single dose of oral busulfan 1.0 mg/kg as the first of 16 doses of busulfan in the conditioning regimen. The remaining busulfan doses were all intravenous busulfan. This amendment became necessary because pharmacokinetic data from the phase 1 study was inadequate, due to numerous patients' data from that study having been incomplete or uninterpretable.

3. Pivotal Study – OMC-BUS-3: A Phase 2 Study of High-Dose Intravenous Busulfan and Cyclophosphamide with Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Hematologic Malignancies


Data Cutoff Date: January 9, 1998

3.1 Rationale
A commonly used conditioning regimen for hematopoietic stem cell transplantation is a non-TBI based regimen that combines the chemotherapeutic agents busulfan and cyclophosphamide. This regimen was originally developed at John’s Hopkins by Santos and Tutschka as busulfan 4mg/kg/d (q 6h) x 4d + cyclophosphamide 50mg/kg/d x 4d (BU/CY200 or BU/CY4). A modified regimen was subsequently developed, which reduces the dose intensity of the cyclophosphamide 60 mg/kg/d x 2d (BU/CY120 or BU/CY2). Oral busulfan is formulated in a 2 mg tablet. The high doses of busulfan required in the described conditioning regimens necessitate that patients swallow a large number of pills with each q 6h dose, which can be particularly difficult as the BU/CY regimen can be associated with significant nausea and vomiting. The sponsor has developed the intravenous formulation of busulfan as a means of easing the administration of busulfan in this situation – eliminating the necessity to swallow multiple pills and theoretically increasing busulfan’s bioavailability by eliminating losses that potentially occur through emesis. This phase 2 trial was designed to demonstrate that the intravenous formulation of busulfan can also induce myeloablation and has an acceptable safety profile in the setting of autologous transplantation.

The intravenous busulfan dose selected for this study, 0.8 mg/kg, was suggested to achieve a similar AUC (plasma concentration) to that of an oral busulfan dose of 1.0 mg/kg in the phase 1 study conducted by the sponsor. A target AUC of <1500 μM x min/l was selected on the basis of literature reports that indicate the risk of hepatic veno-occlusive disease (VOD) increases at higher AUC’s.

3.2 Objectives of the Study

- To administer multiple doses of intravenous busulfan at a dose previously shown to be pharmacokinetically equivalent to the oral formulation when it (the oral drug) is given at a dose of 1 mg/kg, and associated with an AUC less than 1500 μM x min/l, and to administer this dose intravenously over 2 hours every six hours for 16 doses in combination with cyclophosphamide as preparation for autologous hematopoietic stem cell transplantation. The latter could be marrow or peripheral blood derived progenitor cells. Patients with advanced malignancies would be treated in order to demonstrate that this dose and schedule is myeloablative and that engraftment will occur after such myeloablation.

- To determine the median time to engraftment of patients undergoing autologous transplantation after treatment with this regimen. Data regarding relapse rate, long-term disease-free outcome, and overall survival would be collected.

- To determine the toxicity profile of this regimen when utilized as preparation for autologous transplantation.

- To describe the plasma pharmacokinetics of busulfan when administered intravenously in this regimen.

3.3 Study Design

This trial was an open-label, multicenter phase 2 study. Five centers accrued patients.